Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

childhood low-grade glioma News | Kisho

Kisho

Not rare diseases news,
news about your rare disease.

Earlier

A systematic literature review has been conducted on chemotherapy for spinal cord intramedullary pediatric low-grade glioma, providing insights into treatment efficacy and outcomes. This review may inform future clinical practices and research directions in pediatric oncology.

A recent study evaluates the cost-effectiveness of dabrafenib and trametinib for treating pediatric patients with BRAF V600E mutation low-grade glioma in England and Wales. This research could influence treatment decisions and healthcare resource allocation for this patient population.

A Delphi consensus has established recommendations for managing adverse events in pediatric low-grade glioma patients undergoing MAPK-directed therapies. This highlights the need for improved strategies to address these challenges in treatment.

Not rare diseases news,news about your rare disease.

Earlier

A systematic literature review has been conducted on chemotherapy for spinal cord intramedullary pediatric low-grade glioma, providing insights into treatment efficacy and outcomes. This review may inform future clinical practices and research directions in pediatric oncology.

A recent study evaluates the cost-effectiveness of dabrafenib and trametinib for treating pediatric patients with BRAF V600E mutation low-grade glioma in England and Wales. This research could influence treatment decisions and healthcare resource allocation for this patient population.

A Delphi consensus has established recommendations for managing adverse events in pediatric low-grade glioma patients undergoing MAPK-directed therapies. This highlights the need for improved strategies to address these challenges in treatment.

Not rare diseases news,
news about your rare disease.